Takeda commits CHF 5 million to renewable energy for its Neuchâtel site

Takeda Pharmaceutical has announced a CHF 5 million investment in renewable energy for its Neuchâtel facility.

Takeda, a leading global pharmaceutical company, specializes in the production of essential treatments for blood disorders like hemophilia and Von Willebrand disease. The company’s Neuchâtel site focuses on producing treatments for blood disorders such as hemophilia. Employing about 700 people, the site has been pivotal in Takeda’s extensive global operations since its expansion into Western Switzerland following the acquisition of Shire in 2019.

The recently announced CHF 5 million investment will primarily fund the installation of a photovoltaic system set to begin operation in early October 2024. Once completed, this solar energy project will generate 3.7 MW annually, supplying 25% of the plant’s electricity needs. This initiative is part of Takeda’s broader commitment to achieve net-zero carbon emissions by 2035.

In the company’s press release, Jürgen Wagner, Head of the Neuchâtel site, emphasized the project’s alignment with local collaborative efforts, such as apprenticeships that nurture future specialists from the region. This solar power installation will not only reduce the carbon footprint of one of Takeda’s key production sites but also utilize excess energy by feeding it back into the local grid, further supporting the community’s energy needs.